STAT5A and breast carcinoma: At the current efficacy, approximately 20% of cloned Stat5-immunocaptured fragments from T-47D breast cancer cells could be localized within the normal human genome, and Stat5 binding in vitro and in vivo was confirmed in approximately half of those.